Singapore Markets closed

Global Antiemetic Drugs Market 2017-2021: Strong Drug Pipeline to Boost Growth, Reports Technavio

Technavio has published a new report on the global antiemetic drug market from 2017-2021. (Graphic: Business Wire) Multimedia Gallery URL


According to the latest market study released by Technavio, the global antiemetic drugs market is expected to grow at a CAGR of more than 6% during the forecast period.

This Smart News Release features multimedia. View the full release here:

This research report titled ‘Global Antiemetic Drugs Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This report also includes an up to date analysis and forecasts for various market segments and all geographical regions.

According to Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research, “Antiemetic drugs are widely used for the management of various disease conditions and to treat the side effects associated with various drugs. Various formulatory advancements such as formulation in the form of patches, intranasal sprays, and other newer formulatory are expected to fuel antiemetic drugs market.”

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The market research analysis categorizes the global antiemetic drugs market into three major application segments. They are:

  • Chemotherapy
  • Surgery
  • Gastroenteritis


Chemotherapy is a major segment for antiemetic drugs. The treatment of nausea and vomiting caused due to debilitating side effects of chemotherapy occupies the major market. This side effect is known as chemotherapy-induced nausea and vomiting (CINV).

This ever-increasing chemotherapy population need to be treated with better therapeutics to control emetic sensations, and hence, improved quality of life. The data estimated that eight out of 10 people are undergoing chemotherapy encounter with nausea and vomiting as side effects during the treatment. This increasing need is substantiated with the impressive pipeline as most of the pipeline molecules are indicated for CINV. This will fuel the overall market in the forecast period.


Post-operative nausea and vomiting (PONV) is a widespread problem after surgery. The reasons for PONV include usage of anesthesia and side effects associated with opioid analgesics. The global antiemetic surgery treatment market is growing at a high rate compared with other segments, owing to greater acceptance of surgical procedures in recent years due to higher technical advancement making the procedures safe and effective.

“The data estimates that four out of five people undergoing surgery face the issue of PONV. Such high instances of PONV among individuals undergoing surgeries will fuel the antiemetic drugs market growth,” says Sapna.


Gastroenteritis is an infectious disease causing inflammation of the gut. It is more common in children than adults and older people. Much of the pediatric population below five years of age have more than one episodes of gastroenteritis in a year. The severity of disease ranges from GI upset for 1-2 days with mild-to-severe diarrhea with emesis. Many viruses, bacteria, and other microbes are responsible for causing this disease. Rotavirus and norovirus are the major causative agents.

Though the cost of treatment is not so high when compared with other diseases, the overall economic burden of the disease is high. As per the CDC, the global burden of disease is around USD 60 billion, which is mainly contributed by the loss of productivity and hospitalization charges along with various other expenses.

The top vendors highlighted by Technavio’s market research analysts in this report are:

  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like vaccines, oncology, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at

View source version on